HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities
文献类型：期刊论文
| 作者 | Chu, Wendi3,5; Xu, Hui4,5; Wang, Yanfei3,5; Xie, Yongle4,5; Chen, Yi-Li1; Tan, Xiaorong3; Huang, Chenghao6,7; Wang, Guifeng3,5 ; Wang, Qi3; Luo, Wenxin6,7
|
| 刊名 | CLINICAL AND TRANSLATIONAL MEDICINE
 |
| 出版日期 | 2022-04-01 |
| 卷号 | 12期号:4页码:6 |
| ISSN号 | 2001-1326 |
| DOI | 10.1002/ctm2.791 |
| 通讯作者 | Xie, Zuoquan(zqxie@simm.ac.cn) ; Wang, Chunhe(wangc@simm.ac.cn) |
| WOS关键词 | RESISTANCE MECHANISMS ; BREAST-CANCER |
| 资助项目 | Strategic Priority Research Program of the Chinese Academy of Sciences (CAS)[XDA12020360] ; National Natural Science Foundation of China[81872785] ; Institutes for Drug Discovery and Development, CAS[CASIMM0120202007] ; Institutes for Drug Discovery and Development, CAS[CASIMM0120202008] ; Science and Technology Commission of Shanghai Municipality, China[18431907100] ; Science and Technology Commission of Shanghai Municipality, China[21S11904500] ; Collaborative Innovation Cluster Project of Shanghai Municipal Commission of Health and Family Planning[2020CXJQ02] |
| WOS研究方向 | Oncology ; Research & Experimental Medicine |
| 语种 | 英语 |
| 出版者 | JOHN WILEY & SONS LTD |
| WOS记录号 | WOS:000778130600001 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/299937]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xie, Zuoquan; Wang, Chunhe |
| 作者单位 | 1.Shanghai Mabstone Biotechnol Ltd, Shanghai, Peoples R China 2.Dartsbio Pharmaceut Ltd, Zhongshan, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Biotherapeut Discovery Res Ctr, Bldg 1,720 Cai Lun Rd, Shanghai 200126, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, 555 Zu Chong Zhi Rd, Shanghai 200126, Peoples R China 5.Univ Chinese Acad Sci, Beijing, Peoples R China 6.Xiamen Univ, Sch Publ Hlth, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China 7.Xiamen Univ, Sch Life Sci, Xiamen, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chu, Wendi,Xu, Hui,Wang, Yanfei,et al. HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities[J]. CLINICAL AND TRANSLATIONAL MEDICINE,2022,12(4):6. |
| APA | Chu, Wendi.,Xu, Hui.,Wang, Yanfei.,Xie, Yongle.,Chen, Yi-Li.,...&Wang, Chunhe.(2022).HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities.CLINICAL AND TRANSLATIONAL MEDICINE,12(4),6. |
| MLA | Chu, Wendi,et al."HER2/PD1 bispecific antibody in IgG4 subclass with superior anti-tumour activities".CLINICAL AND TRANSLATIONAL MEDICINE 12.4(2022):6. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。